ArticleMolecular genetics and metabolism reports2025
Clinical characterization and genetic analysis of transient abnormal myelopoiesis without the down syndrome phenotype.
Article in Molecular genetics and metabolism reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Dysregulation in Down Syndrome: Implications for Infectious Susceptibility and Vaccine Response.Journal of clinical immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transient abnormal myelopoiesis (TAM) is a congenital leukemia specific to neonates with Down syndrome (DS) or trisomy 21. However, rare cases of TAM can also occur with acquired trisomy 21 mutations or mosaic trisomy 21, leading to potential misdiagnosis due to the absence of the DS phenotypes. Method: We present a case of TAM in a neonate without typical DS phenotypic features. We documented medical records from hospitalizations and a one-year follow-up period. Additionally, through a literature review, we summarized the clinical phenotype and genotypic characteristics observed in similar neonates. Results: Despite the lack of typical DS phenotype the neonate was diagnosed with TAM upon detection of trisomy 21 and the GATA1 gene mutation, the condition resolved spontaneously without requiring chemotherapy. We monitored the neonate for a full year, during which no hematologic or developmental abnormalities were observed. Thirteen previous cases of neonates with TAM but without the DS phenotype have been reported. During the onset of TAM, the presence of trisomy 21 can be detected in peripheral blood cells or bone marrow cells, but some patients may not show evidence of trisomy 21 in fibroblasts. In these patients, trisomy 21 in peripheral blood cells or bone marrow cells may gradually decrease and even disappear as TAM improves. All patients experienced self-limiting remission with a favorable prognosis, although one case progressed to myeloid leukemia associated with DS by age two. Conclusions: A negative obstetrical diagnosis and the absence of clinical DS phenotype should not preclude the consideration of TAM in neonates, especially when trisomy 21 mutations are detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.